Liraglutide for weight loss: what TikTok gets right and wrong
Quick answer
Liraglutide (Saxenda 3 mg/day) is an FDA-approved GLP-1 receptor agonist for chronic weight management in adults meeting BMI criteria, supported by the SCALE trial program showing roughly 8 kg mean weight loss over 56 weeks. The transcript as captured contains no identifiable clinical claims about liraglutide and cannot be evaluated for medical accuracy on its own. Any interest in liraglutide for weight management should involve a licensed prescriber, as it carries a black box warning for thyroid C-cell tumors and requires individualized assessment.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @maramita89 actually say?
Honestly? It's hard to tell. The transcript from this video is garbled to the point of being unreadable. Phrases like "it's all Miranda and nothing is rare" and "Zsc also gets bigger though" don't correspond to any coherent medical claim about liraglutide or weight loss. The caption promises information about liraglutide injections for weight loss, but the transcript doesn't deliver that.
This could be a transcription error, an auto-caption failure, or content that was largely visual with minimal spoken explanation. What we can evaluate is the topic the video is tagged to: liraglutide as a weight-loss injection. That's a real drug with real evidence, and it deserves a straight read.
Does the science back liraglutide for weight loss?
Yes, with caveats worth knowing. Liraglutide (brand name Saxenda at 3 mg daily for obesity, Victoza at lower doses for type 2 diabetes) is an FDA-approved GLP-1 receptor agonist. The evidence base is solid but not spectacular compared to newer agents.
The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, New England Journal of Medicine) followed over 3,700 adults without diabetes for 56 weeks. Participants on liraglutide 3 mg lost an average of 8.4 kg, compared to 2.8 kg on placebo. About 63% of liraglutide users lost at least 5% of body weight versus 27% on placebo. That's meaningful, but it's also a far cry from the 15-20% body weight reductions seen with semaglutide 2.4 mg (Wilding et al., 2021, NEJM) or the even larger numbers from tirzepatide trials. Liraglutide works. It's just no longer the strongest option available.
- Requires daily subcutaneous injection (semaglutide is weekly)
- GI side effects are common: nausea, vomiting, diarrhea
- Weight regain is typical after stopping, as with all GLP-1 drugs
What did they get wrong, or right?
Because the transcript is incoherent, we can't attribute specific errors to the creator. What we can say is that the framing in the caption, positioning liraglutide as an injection to lose weight, is accurate in a basic sense but incomplete in ways that matter.
Liraglutide is a prescription medication approved for specific indications. Saxenda is indicated for adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition. It is not a general-purpose weight-loss tool for anyone who wants to drop a few pounds, and TikTok content tagged with weight-loss hashtags rarely makes that distinction clear.
There's also the compounding issue. With GLP-1 drugs heavily in demand, compounded liraglutide has entered the market. Compounded versions are not FDA-approved and are not equivalent to brand-name Saxenda. Anyone seeing this video and searching for cheap injectable liraglutide online should know that difference is not cosmetic, it's a regulatory and safety distinction.
What should you actually know?
If you're considering liraglutide for weight management, here's the unvarnished version. It works, it's been studied extensively, and it has an established safety profile. But it requires a daily injection, it causes GI side effects in a significant portion of users, and it produces less weight loss than semaglutide or tirzepatide based on current trial data.
Davies et al. (2015, Diabetes Care) and subsequent real-world data confirm that response varies considerably between individuals. Some people lose substantial weight; others see minimal change. A clinician evaluation matters here, not just a TikTok recommendation.
Rare but serious risks include pancreatitis, gallbladder disease, and a black box warning regarding thyroid C-cell tumors based on animal studies. That warning applies to all GLP-1 receptor agonists and should be discussed with a prescriber before starting.
- This is a prescription drug. A legitimate telehealth or in-person evaluation is required.
- Compounded liraglutide is not the same as FDA-approved Saxenda.
- Daily injections are a real adherence challenge compared to weekly semaglutide.
Bottom line on this video
The transcript is too corrupted to fact-check specific claims. The topic, liraglutide for weight loss, is legitimate territory, and the drug itself has a real evidence base. But a video that tags a prescription GLP-1 drug under weight-loss hashtags without visible clinical context does little to help viewers make informed decisions. The science on liraglutide is accessible and worth reading. This video, at least as captured here, doesn't add much to it.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Liraglutide for weight loss: what TikTok gets right and wrong, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Liraglutide for weight loss: what TikTok gets right and wrong is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
Liraglutide (Saxenda 3 mg/day) is an FDA-approved GLP-1 receptor agonist for chronic weight management in adults meeting BMI criteria, supported by the SCALE trial program showing roughly 8 kg mean weight loss over 56 weeks.
FormBlends verdict
Liraglutide (Saxenda 3 mg/day) is an FDA-approved GLP-1 receptor agonist for chronic weight management in adults meeting BMI criteria, supported by the SCALE trial program showing roughly 8 kg mean weight loss over 56 weeks. The transcript as captured contains no identifiable clinical claims about liraglutide and cannot be evaluated for medical accuracy on its own. Any interest in liraglutide for weight management should involve a licensed prescriber, as it carries a black box warning for thyroid C-cell tumors and requires individualized assessment.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Liraglutide (Saxenda 3 mg/day) is an FDA-approved GLP-1 receptor agonist for chronic weight management in adults meeting BMI criteria, supported by the SCALE trial program showing roughly 8 kg mean weight loss over 56 weeks. The transcript as captured contains no identifiable clinical claims about liraglutide and cannot be evaluated for medical accuracy on its own. Any interest in liraglutide for weight management should involve a licensed prescriber, as it carries a black box warning for thyroid C-cell tumors and requires individualized assessment.
- Pi-Sunyer et al. (2015, NEJM) found liraglutide 3 mg produced roughly 8.4 kg mean weight loss over 56 weeks, versus 2.8 kg on placebo.
- Liraglutide produces significantly less weight loss than semaglutide 2.4 mg (approx. 15% body weight, Wilding et al. 2021, NEJM) based on separate trial populations.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Pi-Sunyer et al. (2015, NEJM) found liraglutide 3 mg produced roughly 8.4 kg mean weight loss over 56 weeks, versus 2.8 kg on placebo.
- Liraglutide produces significantly less weight loss than semaglutide 2.4 mg (approx. 15% body weight, Wilding et al. 2021, NEJM) based on separate trial populations.
- Saxenda requires daily subcutaneous injection; semaglutide (Wegovy) is weekly, which is a real-world adherence difference.
- All GLP-1 receptor agonists including liraglutide carry a black box warning for thyroid C-cell tumors based on rodent studies; this must be discussed with a prescriber.
- Compounded liraglutide is not FDA-approved and is not equivalent to brand-name Saxenda, a distinction that matters for safety and efficacy assurance.
- Liraglutide is a prescription medication indicated for BMI 30 or higher, or BMI 27 or higher with a qualifying weight-related condition, not for general cosmetic weight loss.
- Weight regain after stopping liraglutide is well-documented; it is a long-term treatment, not a short course.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Maramita · TikTok creator
10.6K views on this video
Liraglutida inyeccion para bajar de peso. #liraglutida #inyeccionparabajardepeso #bajardepeso
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Maramita, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.